GlassScriptPhysician profile
Albina Kroytor
NPI 1780603803
$7,061.13
in general payments reported to CMS, 2019-2025
33 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,025 · 2022: $1,309 · 2023: $1,389 · 2024: $1,522 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,578 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,578.07 |
| Education | $149.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $954.95 | 2021-2025 | Tremfya, Simponi, Stelara |
| Sun Pharmaceutical Industries INC. | $831.81 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Dermavant Sciences, INC. | $747.81 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $717.59 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $602.94 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $371.88 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $324.03 | 2021-2025 | |
| Incyte Corporation | $298.76 | 2021-2025 | Opzelura |
| Genzyme Corporation | $287.41 | 2021-2025 | |
| Amgen INC. | $232.39 | 2021-2025 | Otezla, Otezla |
| Organon LLC | $213.11 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $201.30 | 2023-2025 | Zoryve |
| Abbvie INC. | $176.27 | 2022-2025 | |
| Galderma Laboratories, L.P. | $171.97 | 2022-2025 | Nemluvio, Oracea, Twyneo |
| Pfizer INC. | $115.36 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.15 | 2021-2024 | Arazlo, Cabtreo |
| Almirall LLC | $85.66 | 2021-2023 | Seysara |
| Epi Health, LLC | $82.01 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $69.68 | 2024-2025 | Valchlor |
| E.R. Squibb & Sons, L.L.C. | $65.33 | 2023 | Sotyktu |
| Botanix Sb INC | $62.42 | 2025 | Sofdra |
| Lnhc, INC | $45.55 | 2025 | Zelsuvmi |
| Ucb, INC. | $42.84 | 2023-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $42.16 | 2022 | |
| Nabriva Therapeutics, Plc | $41.43 | 2022 | |
| Vyne Pharmaceuticals INC. | $28.45 | 2021 | |
| Dermira, INC. | $25.00 | 2021 | |
| Strata Skin Sciences, INC. | $23.52 | 2024 | Xtrac |
| Convatec INC. | $23.07 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.97 | 2021 | |
| Octapharma USA, INC. | $22.67 | 2021 | |
| Sebela Pharmaceuticals INC. | $14.52 | 2022 | |
| Mission Pharmacal Company | $11.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albina Kroytor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.